Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIRA grass pollen allergen immunotherapy trial
2025-521736-10-00Phase 3Authorised
- Sponsor
- LETI Pharma
- Start
- Mar 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of poa pratensis allergen extract and Depigoid Grass Mix in allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by LETI Pharma. Primary endpoint: Mean combined symptom and medication score at peak grass pollen season. Planned start Mar 2026; status: authorised.
02
Drugs
poa pratensis allergen extractDepigoid Grass Mix
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2025-521736-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521736-10-00.